866-997-4948(US-Canada Toll Free)

Celiac Disease - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 82 Pages

Celiac Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogrens syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Celiac Disease - Overview 6
Celiac Disease - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Celiac Disease - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Celiac Disease - Companies Involved in Therapeutics Development 23
Amgen Inc 23
Amyra Biotech AG 23
Calypso Biotech SA 24
Circle33 LLC 24
enGene Inc 25
F. Hoffmann-La Roche Ltd 25
Glenmark Pharmaceuticals Ltd 26
ImmusanT Inc 26
Innovate Biopharmaceuticals Inc 27
Intrexon Corp 27
Sanofi 28
Takeda Pharmaceutical Company Ltd 28
Zedira GmbH 29
Celiac Disease - Drug Profiles 30
AMG-714 - Drug Profile 30
AVX-176 - Drug Profile 32
Biologic for Celiac Disease - Drug Profile 33
BNZ-2 - Drug Profile 34
CALY-002 - Drug Profile 35
ERW-1041E - Drug Profile 36
GBR-830 - Drug Profile 37
Kuma-010 - Drug Profile 38
larazotide acetate - Drug Profile 39
latiglutenase - Drug Profile 42
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile 45
Nexvax-2 - Drug Profile 46
Nexvax-3 - Drug Profile 49
Oligonucleotides for Celiac Disease - Drug Profile 50
Protein for Celiac Disease - Drug Profile 51
Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile 52
Recombinant Protein for Celiac Disease - Drug Profile 53
RG-7625 - Drug Profile 54
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 55
Vaccine for Celiac Disease - Drug Profile 56
Vaccine for Celiac Disease - Drug Profile 58
vedolizumab - Drug Profile 59
ZED-1227 - Drug Profile 66
ZED-754 - Drug Profile 67
Celiac Disease - Dormant Projects 68
Celiac Disease - Product Development Milestones 69
Featured News & Press Releases 69
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Celiac Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Celiac Disease - Pipeline by Amgen Inc, H1 2017
Celiac Disease - Pipeline by Amyra Biotech AG, H1 2017
Celiac Disease - Pipeline by Calypso Biotech SA, H1 2017
Celiac Disease - Pipeline by Circle33 LLC, H1 2017
Celiac Disease - Pipeline by enGene Inc, H1 2017
Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Celiac Disease - Pipeline by ImmusanT Inc, H1 2017
Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H1 2017
Celiac Disease - Pipeline by Intrexon Corp, H1 2017
Celiac Disease - Pipeline by Sanofi, H1 2017
Celiac Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Celiac Disease - Pipeline by Zedira GmbH, H1 2017
Celiac Disease - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Celiac Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *